{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:25:47Z","timestamp":1767774347556,"version":"build-2238731810"},"reference-count":102,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Pleural Mesothelioma (PM) remains a challenging malignancy associated with asbestos exposure and characterized by poor prognosis. This review aims to consolidate recent findings on the efficacy of perioperative therapies encompassing chemotherapy, surgery, and emerging immunotherapy strategies. Current management strategies debate the role of surgery in early-stage patients, particularly due to the limited success of solitary treatment modalities and significant rates of postoperative complications. Retrospective studies indicate that multimodal treatment, incorporating surgical resection with perioperative chemotherapy, can enhance overall survival (OS), especially in favorable prognostic subsets. However, significant randomized trials, notably the MARS and MARS 2 trials, revealed that the addition of aggressive surgical strategies like extrapleural pneumonectomy (EPP) did not confer survival benefits and was accompanied by heightened morbidity. In light of persistent challenges, integrating perioperative chemotherapy\u2014primarily with platinum-based regimens\u2014has shown improved disease control outcomes. Neoadjuvant chemotherapy permits real-time assessment of tumor responsiveness, providing valuable clinical insights for surgical candidacy. The role of immunotherapy, particularly immune checkpoint inhibitors (ICIs), is also under active exploration, with preliminary results suggesting promising activity and manageable safety profiles. In conclusion, while current protocols primarily recommend surgery for a select group of patients, ongoing investigations into neoadjuvant approaches, adjuvant therapies, and novel immunotherapeutic strategies are crucial for developing effective, personalized treatment paradigms for PM. Future efforts should prioritize clinical trials that integrate these therapies within a structured multidisciplinary approach to optimize patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers17193199","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:43:54Z","timestamp":1759250634000},"page":"3199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions"],"prefix":"10.3390","volume":"17","author":[{"given":"Luigi Giovanni","family":"Cecchi","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aliprandi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"De Vincenzo","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-8814","authenticated-orcid":false,"given":"Matteo","family":"Perrino","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Cordua","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8457-3465","authenticated-orcid":false,"given":"Federica","family":"Borea","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cernusco sul Naviglio, ASST Melegnano e Martesana, 20063 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bertocchi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1278-9223","authenticated-orcid":false,"given":"Antonio","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Marulli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Division of Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-0629","authenticated-orcid":false,"given":"Giovanni Luca","family":"Ceresoli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Humanitas Gavazzeni, 24125 Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-1702","authenticated-orcid":false,"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy"},{"name":"Department of Oncology IRCCS, Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Brims, F. (2021). Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13164194"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients","volume":"9","author":"Bovolato","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","unstructured":"(Mesothelioma: Pleural, 2025). National Comprehensive Cancer Network (NCCN), Mesothelioma: Pleural, Version 02.2025."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-Pleural Pneumonectomy versus No Extra-Pleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma: Clinical Outcomes of the Mesothelioma and Radical Surgery (MARS) Randomised Feasibility Study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lim, E., Waller, D., Lau, K., Steele, J., Pope, A., Ali, C., Bilancia, R., Keni, M., Popat, S., and O\u2019Brien, M. (2023). MARS 2: Extended Pleurectomy Decortication and Chemotherapy for Pleural Mesothelioma, SSRN.","DOI":"10.2139\/ssrn.4590908"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.21037\/tlcr.2018.05.07","article-title":"A Randomized Phase II Study of Pleurectomy\/Decortication Preceded or Followed by (Neo-)Adjuvant Chemotherapy in Patients with Early Stage Malignant Pleural Mesothelioma (EORTC 1205)","volume":"7","author":"Raskin","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtho.2024.12.014","article-title":"A Perspective on the MARS2 Trial","volume":"20","author":"Lim","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00595-021-02437-9","article-title":"Surgical Strategy for Malignant Pleural Mesothelioma: The Superiority of Pleurectomy\/Decortication","volume":"52","author":"Kanayama","year":"2022","journal-title":"Surg. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.athoracsur.2014.01.050","article-title":"Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study","volume":"97","author":"Spaggiari","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.athoracsur.2021.04.078","article-title":"Extrapleural Pneumonectomy Versus Pleurectomy\/Decortication for Malignant Pleural Mesothelioma","volume":"113","author":"Zhou","year":"2022","journal-title":"Ann. Thorac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/ejcts\/ezx122","article-title":"Induction Chemotherapy, Extrapleural Pneumonectomy and Adjuvant Radiotherapy for Malignant Pleural Mesothelioma","volume":"52","author":"Casiraghi","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter Trial of Neo-Adjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/17476348.2017.1338951","article-title":"Induction Chemotherapy vs Post-Operative Adjuvant Therapy for Malignant Pleural Mesothelioma","volume":"11","author":"Marulli","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality Therapy for Malignant Pleural Mesothelioma: Results from an EORTC Phase II Multicentre Trial","volume":"36","author":"Baas","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_20","unstructured":"Rea, F., Favaretto, A., Marulli, G., Spaggiari, L., De Pas, M., Ceribelli, A., Paccagnella, A., Crivellari, A., Russo, F., and Kazeem, G. (2013). Phase II Trial of Neoadjuvant Pemetrexed plus Cisplatin Followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma. BMC Cancer, 13."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.ijrobp.2020.11.057","article-title":"Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-Metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial","volume":"109","author":"Trovo","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2020.05.032","article-title":"Addition of Radiotherapy to Surgery and Chemotherapy Improves Survival in Localized Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study","volume":"146","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1002\/mco2.241","article-title":"Survival Benefit after Radiotherapy for Patients with Malignant Pleural Mesothelioma: A Propensity Score\u2014Matched Study","volume":"4","author":"Lian","year":"2023","journal-title":"MedComm"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.21037\/jtd.2019.04.27","article-title":"Defining the Role of Adjuvant Radiotherapy for Malignant Pleural Mesothelioma: A Propensity-Matched Landmark Analysis of the National Cancer Database","volume":"11","author":"Nelson","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13014-015-0575-5","article-title":"Long-Term Results in Malignant Pleural Mesothelioma Treated with Neoadjuvant Chemotherapy, Extrapleural Pneumonectomy and Intensity-Modulated Radiotherapy","volume":"10","author":"Thieke","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijrobp.2014.08.343","article-title":"Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy\/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis","volume":"91","author":"Chance","year":"2015","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1097\/SLA.0000000000004976","article-title":"The Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients with Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis","volume":"277","author":"Raman","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.prro.2018.12.008","article-title":"Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs","volume":"9","author":"Thompson","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","article-title":"The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"14","author":"Gomez","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma with or without Hemithoracic Radiotherapy (SAKK 17\/04): A Randomised, International, Multicentre Phase 2 Trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2019.05.024","article-title":"Pattern of Failure after Adjuvant Radiotherapy Following Extrapleural Pneumonectomy of Pleural Mesothelioma in the SAKK 17\/04 Trial","volume":"138","author":"Riesterer","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for Malignant Pleural Mesothelioma after Radiotherapy (SMART): Final Results from a Single-Centre, Phase 2 Trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as Part of Lung-Sparing Multimodality Therapy in Patients with Malignant Pleural Mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","unstructured":"National Cancer Institute (NCI) (2025, September 18). A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER). (NCT04028570), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04028570?term=NCT04028570&rank=1."},{"key":"ref_35","unstructured":"National Cancer Institute (NCI) (2025, September 18). SMARTEST Trial. (NCT05380713), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05380713."},{"key":"ref_36","unstructured":"National Cancer Institute (NCI) (2025, September 18). Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma (MesoRT). (NCT03269227), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03269227."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Parisi, E., Arpa, D., Ghigi, G., Fabbri, L., Foca, F., Tontini, L., Neri, E., Pieri, M., Cima, S., and Burgio, M.A. (2023). Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT). Cancers, 15.","DOI":"10.3390\/cancers15041057"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton Therapy\u2014Present and Future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2021.1844567","article-title":"Proton Therapy for Thoracic Malignancies: A Review of Oncologic Outcomes","volume":"21","author":"Patel","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_40","first-page":"e1705","article-title":"Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy","volume":"9","author":"Lee","year":"2017","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.prro.2014.11.005","article-title":"Early Experience with Intensity Modulated Proton Therapy for Lung-Intact Mesothelioma: A Case Series","volume":"5","author":"Pan","year":"2015","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.prro.2020.05.004","article-title":"Consensus Statement on Proton Therapy in Mesothelioma","volume":"11","author":"Zeng","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_43","first-page":"595","article-title":"5-Year Prospective Results of Trimodality Treatment for Malignant Pleural Mesothelioma","volume":"47","author":"Pagan","year":"2006","journal-title":"J. Cardiovasc. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/Decortication Is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma","volume":"7","author":"Bille","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejcts.2006.01.015","article-title":"Incidence and Management of Complications after Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma","volume":"29","author":"Opitz","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","article-title":"Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial","volume":"1","author":"Flores","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.athoracsur.2009.05.036","article-title":"Trimodality Therapy for Malignant Pleural Mesothelioma","volume":"88","author":"Buduhan","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality Therapy with Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma","volume":"27","author":"Feld","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_49","first-page":"5393","article-title":"Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM)","volume":"32","author":"Pasello","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.athoracsur.2014.05.071","article-title":"Extrapleural Pneumonectomy After Induction Chemotherapy: Perioperative Outcome in 251 Mesothelioma Patients from Three High-Volume Institutions","volume":"98","author":"Lauk","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-015-0925-1","article-title":"Trimodality Strategy for Treating Malignant Pleural Mesothelioma: Results of a Feasibility Study of Induction Pemetrexed plus Cisplatin Followed by Extrapleural Pneumonectomy and Postoperative Hemithoracic Radiation (Japan Mesothelioma Interest Group 0601 Trial)","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection Margins, Extrapleural Nodal Status, and Cell Type Determine Postoperative Long-Term Survival in Trimodality Therapy of Malignant Pleural Mesothelioma: Results in 183 Patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcts.2009.07.032","article-title":"Three Decades of Experience in the Surgical Multi-Modality Management of Pleural Mesothelioma","volume":"37","author":"Luckraz","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant Pleural Mesothelioma: Clinicopathologic and Survival Characteristics in a Consecutive Series of 394 Patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1245\/s10434-011-2171-8","article-title":"Clinical Impact of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma","volume":"19","author":"Ambrogi","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2009.08.019","article-title":"Survival after Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Chemotherapy with Cisplatin\/Pemetrexed and Radiotherapy","volume":"71","author":"Manegold","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","article-title":"Trimodality Treatment of Malignant Pleural Mesothelioma","volume":"3","author":"Batirel","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of Malignant Pleural Mesothelioma with Chemotherapy Preceding versus after Surgical Resection","volume":"157","author":"Verma","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2016.07.023","article-title":"How Does the Timing of Chemotherapy Affect Outcome Following Radical Surgery for Malignant Pleural Mesothelioma?","volume":"100","author":"Sharkey","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ejcts.2010.01.008","article-title":"Effect of Induction Chemotherapy on Lung Function and Exercise Capacity in Patients Affected by Malignant Pleural Mesothelioma","volume":"37","author":"Marulli","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_61","unstructured":"National Cancer Institute (NCI) (2025, September 18). Pleurectomy\/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients with Locally Advanced Malignant Pleural Mesothelioma. (NCT00715611), Available online: https:\/\/clinicaltrials.gov\/study\/NCT00715611?term=NCT00715611&rank=1."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_63","unstructured":"National Cancer Institute (NCI) (2024, February 06). Pleurectomy\/Decortication (P\/D) Preceded or Followed by Chemotherapy in Patients with Early Stage MPM. (NCT02436733), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02436733?term=NCT02436733&rank=1."},{"key":"ref_64","unstructured":"National Cancer Institute (NCI) (2025, September 18). Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM). (NCT03760575), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03760575?term=NCT03760575&rank=1&tab=table."},{"key":"ref_65","unstructured":"National Cancer Institute (NCI) (2025, September 18). A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma. (NCT04162015), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04162015?term=NCT04162015&rank=1."},{"key":"ref_66","unstructured":"National Cancer Institute (NCI) (2025, September 18). Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma. (NCT03918252), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03918252?term=NCT03918252&rank=1."},{"key":"ref_67","unstructured":"National Cancer Institute (NCI) (2025, September 18). Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients with Stage I-III Pleural Malignant Mesothelioma. (NCT03228537), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03228537?term=NCT03228537&rank=1&tab=table."},{"key":"ref_68","unstructured":"National Cancer Institute (NCI) (2025, September 19). Testing the Addition of Immunotherapy Before Surgery for Patients with Sarcomatoid Mesothelioma. (NCT05647265), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05647265?term=NCT05647265&rank=1."},{"key":"ref_69","unstructured":"National Cancer Institute (NCI) (2025, September 19). Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA). (NCT06155279), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06155279?term=NCT06155279&rank=1."},{"key":"ref_70","unstructured":"National Cancer Institute (NCI) (2025, September 20). Neoadjuvant Durvalumab and Tremelimumab with and Without Chemotherapy for Mesothelioma. (NCT05932199), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05932199?term=NCT05932199&rank=1."},{"key":"ref_71","unstructured":"National Cancer Institute (NCI) (2025, September 18). Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso). (NCT04996017), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04996017?term=NCT04996017&rank=1."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20411\/pai.v9i1.647","article-title":"Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin\u2019s Lymphoma","volume":"9","author":"Giraudo","year":"2024","journal-title":"Pathog. Immun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.xjon.2023.09.005","article-title":"Extended Pleurectomy\/Decortication and Hyperthermic Intraoperative Intrapleural Cisplatin Perfusion for Malignant Pleural Mesothelioma","volume":"16","author":"Okubo","year":"2023","journal-title":"JTCVS Open"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bongiolatti, S., Mazzoni, F., Salimbene, O., Caliman, E., Ammatuna, C., Comin, C.E., Antonuzzo, L., and Voltolini, L. (2021). Induction Chemotherapy Followed by Pleurectomy Decortication and Hyperthermic Intraoperative Chemotherapy (HITHOC) for Early-Stage Epitheliod Malignant Pleural Mesothelioma\u2014A Prospective Report. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235542"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12957-025-03748-8","article-title":"Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma after Cytoreductive Surgical Procedures: A Systematic Review","volume":"23","author":"Elsayed","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1245\/s10434-008-9899-9","article-title":"Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution\u2019s Experience","volume":"15","author":"Kappers","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic Intraoperative Pleural Cisplatin Chemotherapy Extends Interval to Recurrence and Survival among Low-Risk Patients with Malignant Pleural Mesothelioma Undergoing Surgical Macroscopic Complete Resection","volume":"145","author":"Sugarbaker","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s13304-024-01986-1","article-title":"Effect of Intraoperative Hyperthermic Intrathoracic Chemotherapy after Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma: A Comparative Study","volume":"76","author":"Elsayed","year":"2024","journal-title":"Updat. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e003032","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: The Tumor-Immune Microenvironment of Mesothelioma and Implications for Checkpoint Blockade Efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and Predictive Aspects of the Tumor Immune Microenvironment and Immune Checkpoints in Malignant Pleural Mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic Impact of PD-1 and PD-L1 Expression in Malignant Pleural Mesothelioma: An International Multicenter Study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.athoracsur.2020.10.031","article-title":"Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma","volume":"112","author":"Lee","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus Chemotherapy versus Chemotherapy in Untreated Advanced Pleural Mesothelioma in Canada, Italy, and France: A Phase 3, Open-Label, Randomised Controlled Trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"175883592096236","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and Prognosis in Patients with Malignant Pleural Mesothelioma: A Meta-Analysis and Bioinformatics Study","volume":"12","author":"Jin","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"TPS8591","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8591","article-title":"Phase III Study with Atezolizumab versus Placebo in Patients with Malignant Pleural Mesothelioma after Pleurectomy\/Decortication (AtezoMeso Study)","volume":"40","author":"Pagano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_87","unstructured":"National Cancer Institute (NCI) (2025, September 18). Nivolumab with Chemotherapy in Pleural Mesothelioma After Surgery. (NCT04177953), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04177953?term=NCT04177953&rank=1&tab=table."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cllc.2020.10.005","article-title":"A Phase II Trial of Nivolumab with Chemotherapy Followed by Maintenance Nivolumab in Patients with Pleural Mesothelioma After Surgery: The NICITA Study Protocol","volume":"22","author":"Shah","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus Adjuvant Ipilimumab plus Nivolumab in Macroscopic Stage III Melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S870","DOI":"10.1016\/j.jtho.2021.08.076","article-title":"OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma","volume":"16","author":"Tsao","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_94","unstructured":"National Cancer Institute (NCI) (2025, September 18). Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma. (NCT04040231), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04040231?term=NCT04040231&rank=1."},{"key":"ref_95","unstructured":"National Cancer Institute (NCI) (2025, September 18). Poly-ICLC (Hiltonol\u00ae) Vaccine In Malignant Pleural Mesothelioma. (NCT04525859), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04525859."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"CT205","DOI":"10.1158\/1538-7445.AM2022-CT205","article-title":"Abstract CT205: A Phase I\/Ib Trial of Intratumoral Poly-ICLC in Resectable Malignant Pleural Mesothelioma","volume":"82","author":"Fitzgerald","year":"2022","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_98","unstructured":"National Cancer Institute (NCI) (2025, September 18). dENdritic Cell Therapy Combined with SURgEry in Mesothelioma (ENSURE). (NCT05304208), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05304208?tab=table."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Castelletti, L., Yeo, D., Van Zandwijk, N., and Rasko, J.E.J. (2021). Anti-Mesothelin CAR T Cell Therapy for Malignant Mesothelioma. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00264-1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ejcts\/ezx079","article-title":"Pleurectomy-decortication in malignant pleural mesothelioma: Are different surgical techniques associated with different outcomes? Results from a multicentre study","volume":"52","author":"Marulli","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."}],"updated-by":[{"DOI":"10.3390\/cancers18010103","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000}}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:43:33Z","timestamp":1767602613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":102,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193199"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193199","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}